Business
ChromaDex Signs Sinopharm Xingsha Agreement to Accelerate Cross-Border Sales of Tru Niagen® into Mainland China
Under the distribution agreement, all cross-border operations in the region will be transitioned to Sinopharm, with Sinopharm investments to amplify Tru
About this update from Niagen Bioscience, Inc.
[{"type":"text","content":"\nUnder the distribution agreement, all cross-border operations in the region will be transitioned to Sinopharm, with Sinopharm investments to amplify Tru Niagen® brand awareness, as a first step in ChromaDex’s recently announced China Joint Venture agreement\n\n LOS ANGELES--(BUSINESS WIRE)--\nChromaDex Corp. (NASDAQ:CDXC) (“the Company”) a global bioscience company dedicated to healthy aging, today announced a signed distribution agreement with Sinopharm Xingsha to accelerate cross-border sales of Tru Niagen® into mainland China. Tru Niagen® features ChromaDex’s proprietary Niagen® (patented nicotinamide riboside or NR) ingredient, which is the world’s most efficient NAD+ (nicotinamide adenine dinucleotide) precursor on the market, particularly over NMN (nicotinamide mononucleotide). Sinopharm Xingsha is the main platform of Sinopharm Group for food supplements and healthcare products and is a subsidiary of Sinopharm Group, with businesses including pharmaceutical manufacturing, marketing and distribution of drugs, and food supplements and healthcare products. Sinopharm Group is a large healthcare group directly under the State-owned Assets Supervision and Administration Commission (SASAC) of the State Council, with a full value chain in the industry covering R&D, manufacturing, logistics and distribution, retail chains, healthcare, engineering services, exhibitions and conferences, international business, and financial services. In line with ChromaDex’s recent China Joint Venture announcement, Sinopharm Xingsha will collaborate to secure Health Food Registration in China.\nThis press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220610005056/en/ChromaDex CEO, Rob Fried, signs Sinopharm Xingsha distribution agreement (Photo: Business Wire)\n“We are delighted to announce the official launch of our partnership with Sinopharm Xingsha which will support accelerated cross-border sales of Tru Niagen® across mainland China,” said Rob Fried, CEO of ChromaDex. “China’s marketplace remains strategically important with more than 260 million people over the age of 60 and it is our intention to become the leading provider of NAD+ boosting supplements in the market.”\n\nAccording to a recently commissioned “Sizing the Market for NAD+ Supplements in China” report by Euromonitor, white space...